Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
MLN8237 is currently in Phase II study for treatment of patients with ovarian
Formula: C14H11N3O
intrathecally) dose-dependently prevents CFA-induced pain behavior and the associates SGK1 phosphorylation
and potential for combination in preclinical models
When Delpazolid (LCB-0371) is administered at 100 mg/kg daily (by gavage)
MGCD0103 - CAS# 726169-73-9 Catalog No.:M6555-10 MLN8237 is currently in PhaseMGCD0103, also known as Mocetinostat, CAS No. 726169 73 9, is a rationally designed, orally available, Class 1 selective, small molecule, 2 aminobenzamide HDAC inhibitor with potential antineoplastic activity. MGCD0103 binds to and inhibits Class 1 isoforms of HDAC, specifically HDAC 1, 2 and 3, which may result in epigenetic changes in tumor cells and so tumor cell death; although the exact mechanism has yet to be defined, tumor cell death may occur